Adalvo has submitted EU DCPs for Linagliptin 5mg film-coated tablets, reinforcing its commitment to expanding its diabetes portfolio. Approval is expected by October 2025.
This submission aligns with Adalvo’s focused IP strategy, supporting rapid market access and positioning Adalvo to meet the growing demand in the diabetes market.
Linagliptin, based on the reference brand Trajenta, is indicated for lowering blood sugar levels in patients with type 2 diabetes and generated $2.6 billion in global sales in 2023, according to IQVIA.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner with Adalvo for portfolio expansion and growth in diabetes care.